A carregar...
Managing treatment–related adverse events associated with Alk inhibitors
Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients. Because of the...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3921027/ https://ncbi.nlm.nih.gov/pubmed/24523601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.21.1740 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|